Keynote Speakers
David Hoon Professor, Director Department of Translational Molecular Medicine, John Wayne Cancer Institute |
Klaus Pantel Chairman, Department of Tumor Biology, University Medical Center Hamburg-Eppendorf |
Robert Wassman Chief Medical Officer, Rosetta Genomics |
Martin Siaw Associate Scientific Director, Quest Diagnostics Nichols Institute |
Walter Koch Vice President, Roche Molecular Systems |
Yoshiya Oda President, Eisai Inc |
|
Oscar Puig Biomarker Leader, Hoffmann La Roche |
Michael Heller Professor, Dept Bioengineering, University of California-San Diego |
Nicholas Dracopoli Vice President/Head, Johnson & Johnson |
Ruth Katz Professor of Pathology, Chief Image Analysis Laboratory, Chief Research Cytopathology, MD Anderson Cancer Center |
Scott Patterson Executive Director, Amgen Inc |
OverviewBiofluid Biopsies and Companion Diagnostics 2014 brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby Circulating Biomarkers of various classes are being evaluated for their potential to be developed into diagnostics for cancer as well as other disease classes.
The Biofluid Biopsies Conference Track focuses primarily on blood-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), and protein-based circulating biomarkers. There is much interest in the potential of ctDNA for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this track bring together the most up-to-date information and current state-of-the-field.
Major theme of this conference track is to explore the potential of various circulating biomarker classes, such as circulating-free DNA (cfDNA), CTCs, and Extracellular Vesicles (EVs), for Biofluid-based Biopsies and Patient Monitoring.
The Companion Diagnostics Conference Track brings together presenters from around the world to offer a comprehensive picture from research, commercial, and regulatory perspectives as to the deployment of biomarkers for precision medicine, and technical as well as economic and regulatory considerations in the development of companion diagnostics for the different cancer sub-classes as well as other disease areas.
Agenda and Information for:
|
|
|
Corporate Sponsors
|
Media Sponsors
|
|
Networking
|
|
|
|
|
|